Synonyms: dual GSK-3β/AChE inhibitor
Compound class:
Synthetic organic
Comment: Compound 2f is a hybrid molecule that combines a selective glycogen synthase kinase-3β (GSK-3β) inhibitor (GSK-3β inhibitor 3 [PMID: 25845281]) with the acetylcholinesterase (AChE) inhibitor tacrine [1]. It is predicted that this approach may improve clinical efficacy in Alzheimer's disease (AD) by simultaneously targeting these two crucial AD targets, and presents as a useful tool for furthering AD drug discovery. It is active in vitro and in vivo.
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
Bioactivity Comments |
Compound 2f inhibits β-amyloid self-aggregation by 46%, inhibits hyperphosphorylation of tau protein in mouse neuroblastoma N2a-Tau cells, and ameliorates the cognitive disorders in scopolamine-treated ICR mice [1]. These effects indicate that dual GSK-3β/AChE pathway inhibition is a promising strategy for AD therapy. |
Selectivity at enzymes | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
|